325 related articles for article (PubMed ID: 18022018)
21. Clinical spectrum of Anderson Fabry disease in a Romanian family.
Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
[TBL] [Abstract][Full Text] [Related]
22. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
Germain DP
J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
[TBL] [Abstract][Full Text] [Related]
23. Unexpected Fabry disease in a renal allograft kidney: an underrecognized cause of poor allograft function.
Kochar O; Wick MR; Kerr SE; Oglesbee D; Cathro HP
Ultrastruct Pathol; 2011 Apr; 35(2):92-6. PubMed ID: 21299350
[TBL] [Abstract][Full Text] [Related]
24. A successful approach for the detection of Fabry patients in Argentina.
Rozenfeld PA; Tarabuso A; Ebner R; Ramallo G; Fossati CA
Clin Genet; 2006 Apr; 69(4):344-8. PubMed ID: 16630168
[TBL] [Abstract][Full Text] [Related]
25. Bilateral femoral head and distal tibial osteonecrosis in a patient with Fabry disease.
Lien YH; Lai LW
Am J Orthop (Belle Mead NJ); 2005 Apr; 34(4):192-4. PubMed ID: 15913175
[TBL] [Abstract][Full Text] [Related]
26. Pediatric Fabry disease.
Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
[TBL] [Abstract][Full Text] [Related]
27. Hemizygous Fabry disease associated with IgA nephropathy: a case report.
Shimohata H; Yoh K; Takada K; Tanaka H; Usui J; Hirayama K; Kobayashi M; Yamagata K
J Nephrol; 2009; 22(5):682-4. PubMed ID: 19810002
[TBL] [Abstract][Full Text] [Related]
28. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
Yoshimitsu M; Higuchi K; Ramsubir S; Nonaka T; Rasaiah VI; Siatskas C; Liang SB; Murray GJ; Brady RO; Medin JA
Gene Ther; 2007 Feb; 14(3):256-65. PubMed ID: 16929352
[TBL] [Abstract][Full Text] [Related]
29. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease.
Ishii S; Chang HH; Yoshioka H; Shimada T; Mannen K; Higuchi Y; Taguchi A; Fan JQ
J Pharmacol Exp Ther; 2009 Mar; 328(3):723-31. PubMed ID: 19106170
[TBL] [Abstract][Full Text] [Related]
30. [Enzyme replacement therapy in Fabry's disease].
Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
[TBL] [Abstract][Full Text] [Related]
31. Impact of posttransplant diabetes mellitus on graft function in autosomal dominant polycystic kidney disease patients after kidney transplantation.
Pietrzak-Nowacka M; Safranow K; Dziewanowski K; Debska-Slizień A; Głyda M; Gołembiewska E; Jankowska M; Nowosiad M; Rutkowski B; Ciechanowski K
Ann Acad Med Stetin; 2008; 54(1):41-8. PubMed ID: 19127808
[TBL] [Abstract][Full Text] [Related]
32. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.
Garman SC; Garboczi DN
J Mol Biol; 2004 Mar; 337(2):319-35. PubMed ID: 15003450
[TBL] [Abstract][Full Text] [Related]
33. Transplantation: impact of pretransplant renal insufficiency.
Bahirwani R; Campbell MS; Siropaides T; Markmann J; Olthoff K; Shaked A; Bloom RD; Reddy KR
Liver Transpl; 2008 May; 14(5):665-71. PubMed ID: 18433034
[TBL] [Abstract][Full Text] [Related]
34. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
35. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
[TBL] [Abstract][Full Text] [Related]
36. [Clinical courses of two male siblings on hemodialysis for Fabry disease ].
Itoh K; Tanaka M; Matsushita K; Miyamura N; Nishida K; Araki E; Nonoguchi H; Tomita K
Nihon Jinzo Gakkai Shi; 2005; 47(2):121-7. PubMed ID: 15859134
[TBL] [Abstract][Full Text] [Related]
37. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
[TBL] [Abstract][Full Text] [Related]
38. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
Fan JQ; Ishii S; Asano N; Suzuki Y
Nat Med; 1999 Jan; 5(1):112-5. PubMed ID: 9883849
[TBL] [Abstract][Full Text] [Related]
39. Remarkable variability in renal disease in a large Slovenian family with Fabry disease.
Verovnik F; Benko D; Vujkovac B; Linthorst GE
Eur J Hum Genet; 2004 Aug; 12(8):678-81. PubMed ID: 15162124
[TBL] [Abstract][Full Text] [Related]
40. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature.
Müller-Höcker J; Schmid H; Weiss M; Dendorfer U; Braun GS
Hum Pathol; 2003 Mar; 34(3):285-9. PubMed ID: 12673565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
